Tetraphase Pharmaceuticals
Biotechnology ResearchUnited States51-200 Employees
Tetraphase is fighting one of the most significant threats to humanity — antibiotic resistance — through the promise of our technology and the passion of our people. We are committed to making novel antibiotics accessible to all patients in need. According to The Review on Antimicrobial Resistance (May 2016), by 2050, antimicrobial resistance is projected to kill more people than cancer and diabetes combined. At Tetraphase, the fight against antimicrobial resistance is at the core of who we are as a company. It unites us in a common goal and fuels our determination to develop new antibiotics that can overcome the challenges of drug-resistant bacteria and ensure the availability of effective treatments in the future. By virtue of our size, novel technology, and well-defined mission targeting antibiotic resistance, Tetraphase has the focus and flexibility to explore a broad range of antibiotic solutions. Our lead product, XERAVA, is approved for the treatment of complicated intra-abdominal infections (cIAI), find out more at XERAVA.com
1-888-653-2347 
support@leadiq.com 
